Who are Processa Pharmaceuticals, Inc.'s main suppliers?

Processa Pharmaceuticals, Inc. (PCSA) key suppliers include: CONTRACT-RESEARCH-ORGANIZATIONS, APOSENSE-LTD, ELION, ELION-ONCOLOGY-INC, SUN-PHARMACEUTICALS and 8 more. View the full supplier network at chainsifter.com/chain/PCSA.

Who are Processa Pharmaceuticals, Inc.'s major customers?

Processa Pharmaceuticals, Inc. (PCSA) key customers include: A-G-P-ALLIANCE-GLOBAL-PARTNERS. View the full customer network at chainsifter.com/chain/PCSA.

What sector is Processa Pharmaceuticals, Inc. in?

Processa Pharmaceuticals, Inc. (PCSA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Processa Pharmaceuticals, Inc. Supplier List (PCSA): 13 Verified Suppliers

13Suppliers

1Customers

3Debt Items

6Related Chains

Source-Backed Evidence Depth

Processa Pharmaceuticals, Inc. (PCSA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships

4Distinct source URLs

12High confidence

0.819Average confidence

2026-09-14Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Processa Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CONTRACT-RESEARCH-ORGANIZATIONS	CONTRACT-RESEARCH-ORGANIZATIONS	92%	We enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further develop our products.
APOSENSE-LTD	APOSENSE-LTD	90%	10.6 License Agreement with Aposense, Ltd. dated May 24, 2020
ELION	ELION	90%	On May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between the Company and Elion as a result of the Company's alleged breach thereof.
ELION-ONCOLOGY-INC	ELION-ONCOLOGY-INC	90%	10.8 License Agreement with Elion Oncology, Inc.
SUN-PHARMACEUTICALS	SUN-PHARMACEUTICALS	90%	10.2 License Option Agreement with Sun Pharmaceuticals
SUN-PHARMACEUTICALS-INDUSTRIES-LIMITED	SUN-PHARMACEUTICALS-INDUSTRIES-LIMITED	90%	We are required to pay Sun Pharma royalties, on a product by product basis, on future worldwide net sales, or pay a percentage of any sublicense revenue
YUHAN-CORPORATION	YUHAN-CORPORATION	90%	10.7 License Agreement with Yuhan Corporation
FENC	Fennec Pharmaceuticals Inc.	72%	Reciprocal relationship from FENC graph: includes stock options and warrants, if dilutive, as determined using the if-converted method and treasury methods. Reclassifications Certain prior period a…
IRD	Opus Genetics, Inc.	72%	Reciprocal relationship from IRD graph: 2 million and $ 11.0 million, respectively, related to the output of ongoing research and development services and to a much lesser extent royalty payments. Re…
CORLYST-LLC	CORLYST-LLC	62%	$ 2,834,405 (1) Research and development personnel costs include employee stock-based compensation expense of $ 17,144 and $ 46,720 for the three months ended March 31, 2026 and 2025, respectively. (…
OCUPHIRE-PHARMA-INC	OCUPHIRE-PHARMA-INC	62%	d twenty (120) days to finish any remaining due diligence and enter into the license agreement. On October 11, 2025, Intact opted to extend the due diligence deadline by an additional one hundred and…
OVERVIEW-PROCESSA-PHARMACEUTICALS-INC	OVERVIEW-PROCESSA-PHARMACEUTICALS-INC	62%	d twenty (120) days to finish any remaining due diligence and enter into the license agreement. On October 11, 2025, Intact opted to extend the due diligence deadline by an additional one hundred and…
TERM-SHEET-YUHAN-CORPORATION	TERM-SHEET-YUHAN-CORPORATION	62%	d twenty (120) days to finish any remaining due diligence and enter into the license agreement. On October 11, 2025, Intact opted to extend the due diligence deadline by an additional one hundred and…

Processa Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
A-G-P-ALLIANCE-GLOBAL-PARTNERS	A-G-P-ALLIANCE-GLOBAL-PARTNERS	90%	10.10 Sales Agreement, dated May 21, 2024, by and among Processa Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners

Processa Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
PCSA-DEBT-11696	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-03-31.
PCSA-DEBT	Debt stack $257,507	90%	Market cache reports total debt of $257,507.
PCSA-DEBT-11695	Warrants outstanding: 100000	90%	xbrl warrant detail from xbrl 2023-12-31.

Processa Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Processa Pharmaceuticals, Inc..

Processa Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
PCSA-OWNER-BANK-OF-AMERICA-CORP-DE	BANK OF AMERICA CORP /DE/	90%	13F overlay lists BANK OF AMERICA CORP /DE/ as top holder; 1 tracked holders.

Processa Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
FENC	Fennec Pharmaceuticals Inc.	100.00	1	['supplier']
IRD	Opus Genetics, Inc.	100.00	1	['supplier']
ORANY	ORANGE	50.00	2
MYGN	Myriad Genetics, Inc.	50.00	2
OCUL	Ocular Therapeutix, Inc.	50.00	2
PLAB	Photronics, Inc.	50.00	2

Processa Pharmaceuticals, Inc. Supply Chain